Free Trial

Pasithea Therapeutics (KTTA) Competitors

Pasithea Therapeutics logo
$0.74 -0.01 (-1.44%)
Closing price 07/3/2025 03:35 PM Eastern
Extended Trading
$0.74 0.00 (-0.14%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KTTA vs. GBIO, FGEN, FNCH, DARE, SLGL, MIRA, NAII, BCTX, RLMD, and DRRX

Should you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include Generation Bio (GBIO), FibroGen (FGEN), Finch Therapeutics Group (FNCH), Dare Bioscience (DARE), Sol-Gel Technologies (SLGL), MIRA Pharmaceuticals (MIRA), Natural Alternatives International (NAII), Briacell Therap (BCTX), Relmada Therapeutics (RLMD), and DURECT (DRRX). These companies are all part of the "pharmaceutical products" industry.

Pasithea Therapeutics vs. Its Competitors

Pasithea Therapeutics (NASDAQ:KTTA) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

In the previous week, Pasithea Therapeutics' average media sentiment score of 0.00 equaled Generation Bio'saverage media sentiment score.

Company Overall Sentiment
Pasithea Therapeutics Neutral
Generation Bio Neutral

Pasithea Therapeutics has a net margin of 0.00% compared to Generation Bio's net margin of -292.92%. Generation Bio's return on equity of -75.84% beat Pasithea Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A -88.14% -81.21%
Generation Bio -292.92%-75.84%-30.40%

Pasithea Therapeutics has higher earnings, but lower revenue than Generation Bio. Generation Bio is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/A-$13.90M-$10.60-0.07
Generation Bio$19.89M1.17-$131.67M-$1.08-0.32

Generation Bio has a consensus target price of $7.33, suggesting a potential upside of 2,007.28%. Given Generation Bio's stronger consensus rating and higher possible upside, analysts clearly believe Generation Bio is more favorable than Pasithea Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pasithea Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Generation Bio
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Pasithea Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500.

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Generation Bio shares are held by institutional investors. 16.3% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 21.1% of Generation Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Generation Bio beats Pasithea Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KTTA vs. The Competition

MetricPasithea TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.45M$2.92B$5.56B$9.05B
Dividend YieldN/A2.44%5.24%3.99%
P/E Ratio-0.0721.5627.6520.23
Price / SalesN/A283.26419.56119.26
Price / CashN/A41.7026.2128.59
Price / Book0.077.538.035.65
Net Income-$13.90M-$55.14M$3.18B$249.15M
7 Day Performance2.18%4.61%2.93%3.28%
1 Month Performance-16.80%0.90%1.72%3.95%
1 Year Performance-85.48%5.40%34.39%20.98%

Pasithea Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KTTA
Pasithea Therapeutics
0.988 of 5 stars
$0.74
-1.4%
N/A-85.5%$5.45MN/A-0.073Gap Down
GBIO
Generation Bio
2.9469 of 5 stars
$0.32
0.0%
$7.33
+2,191.7%
-83.9%$21.46M$19.89M-0.30150High Trading Volume
FGEN
FibroGen
4.7129 of 5 stars
$5.27
-0.6%
$250.00
+4,643.8%
-68.5%$21.42M$29.62M-2.11570Positive News
Insider Trade
Gap Up
FNCH
Finch Therapeutics Group
1.0554 of 5 stars
$13.20
flat
N/A+929.5%$21.20M$110K-1.50190News Coverage
DARE
Dare Bioscience
1.5766 of 5 stars
$2.37
-0.8%
$12.00
+406.3%
-23.8%$21.15M$10K-13.9430News Coverage
SLGL
Sol-Gel Technologies
2.6261 of 5 stars
$7.40
-0.1%
$40.00
+440.9%
-13.3%$20.61M$11.54M-1.5750
MIRA
MIRA Pharmaceuticals
2.6126 of 5 stars
$1.21
flat
$14.00
+1,057.0%
+101.0%$20.47MN/A-2.372Gap Up
NAII
Natural Alternatives International
1.0051 of 5 stars
$3.26
-0.6%
N/A-42.1%$20.27M$113.80M-2.35290Positive News
BCTX
Briacell Therap
2.3366 of 5 stars
$2.86
-2.7%
$32.00
+1,018.9%
-80.8%$19.92MN/A-0.348
RLMD
Relmada Therapeutics
4.6142 of 5 stars
$0.62
+2.6%
$5.00
+711.6%
-79.2%$19.92MN/A-0.2510Gap Up
DRRX
DURECT
0.5358 of 5 stars
$0.64
+0.8%
N/A-49.1%$19.72M$2.03M-4.2780Gap Down

Related Companies and Tools


This page (NASDAQ:KTTA) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners